TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28647451
Drug: Mindfulness, cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness, cognitive based therapy
Study: 12164031
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral iron supplementation (100 mg elemental iron)
Study: 12164031
Drug: Thrice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice weekly oral iron supplementation (100 mg elemental iron)
Study: 12164031
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral iron supplementation (100 mg elemental iron)
Study: 27354202
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill with conditioned stimulus (novel-tasting drink)
Study: 20216117
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) dosing regimens (fixed and concentration-controlled)
Study: 14696994
Drug: Resonance therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resonance therapy (RT; n = 19)
Study: 15220165
Drug: Epidural oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural oxycodone 6 mg day(‐1)
Study: 15220165
Drug: Epidural oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural oxycodone 12 mg day(‐1)
Study: 15220165
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 6 mg day(‐1)
Study: 3290622
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin treatment (UCT)
Study: 1375801
Drug: Risperidone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (12 mg daily)
Study: 1375801
Drug: Haloperidol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (10 mg daily)
Study: 7511740
Drug: enalapril, lisinopril,
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril, lisinopril, or perindopril (ACE inhibitors) for 8-12 weeks
Study: 7511740
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor monotherapy
Study: 28593720
Drug: Phytoestrogen-rich natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytoestrogen-rich natural preparation Karinat
Study: 26248676
Drug: Immediate vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate vaccination with rVSV‐ZEBOV (one dose of 2×10^7 plaque‐forming units, administered intramuscularly)
Study: 23065050
Drug: 27-G Whitacre
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 27-G Whitacre spinal needle
Study: 23065050
Drug: Both Whitacre
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Whitacre and Quincke needles with 1.2 ml of 0.5% plain bupivacaine
Study: 22256634
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (Glucosamine Hydrochloride capsules, 2 capsules, 3 times per day)
Study: 19301989
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR (50 or 100 mg, q4-6h, p.o.)
Study: 19301989
Drug: Oxycodone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone IR (10 or 15 mg, q4-6h, p.o.)
Study: 16702891
Drug: Pagoclone (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pagoclone (4.8 mg)
Study: 16702891
Drug: Pagoclone (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pagoclone (1.2 mg)
Study: 16702891
Drug: Diazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (30 mg)
Study: 15349004
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (75 to 225 mg/d)
Study: 11392066
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg chlorpheniramine (CPM) before surgery (Control group C, n = 22)
Study: 11392066
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg dextromethorphan (DM) and 20 mg CPM before surgery (group B, n = 22)
Study: 9034938
Drug: nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine 300 mg b.i.d. (N2)
Study: 9034938
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg b.i.d. (R2)
Study: 9034938
Drug: nizatidine 300
Normalized name: nizatidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nizatidine 300 mg q.h.s. (N1)
Study: 9034938
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg q.h.s. (R1)
Study: 1325613
Drug: rHuEpo at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo at an initial dose of 50 U/kg thrice weekly, adjusted to maintain Hb 105-120 g/l (group 1)
Study: 1325613
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose of rHuEpo adjusted to maintain Hb 105-120 g/l (group 2)
Study: 1325613
Drug: rHuEpo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo therapy (both groups)
Study: 1325613
Drug: rHuEpo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo therapy (group 1)
Study: 26088854
Drug: Restrictive volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive volume of intraoperative fluid (≤8 mL/kg/h)
Study: 26088854
Drug: Liberal volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal volume of intraoperative fluid (>8 mL/kg/h)
Study: 23819476
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus additional early initiation of secondary prevention drugs (blood-pressure lowering protocol, simvastatin 40 mg, dipyridamole 200 mg m/r bd)
Study: 23819476
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (initiation of aspirin and referral to a TIA clinic)
Study: 16173864
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) with homework assignments
Study: 12695287
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg BID)
Study: 7751429
Drug: Indenolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indenolol (120 mg)
Study: 2208416
Drug: Xintongkang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xintongkang capsule
Study: 2208416
Drug: Persantin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persantin and aspirin (Control)
Study: 27710700
Drug: Pharmacotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy and weight-bearing and balance-training exercises (Control)
Study: 21256048
Drug: Tadalafil 40
Normalized name: tadalafil 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 40 mg add-on to bosentan
Study: 21256048
Drug: Tadalafil monotherapy
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil monotherapy and as add-on
Study: 19120729
Drug: Suction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suction of oral secretion before each positional care
Study: 2126475
Drug: Natural porcine
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Natural porcine surfactant treatment
Study: 18254487
Drug: Parecoxib, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib, 40 mg
Study: 16494640
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of ramipril 2.5 mg/felodipine ER 2.5 mg
Study: 10764312
Drug: Systemic corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroid treatment arm
Study: 10764312
Drug: Treatment failure
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment failure (defined as death, intubation, readmission for COPD, or intensification of drug therapy)
Study: 17634903
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tropisetron intravenously for 5 days
Study: 11590553
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (ERT) with estradiol 2 mg/day for 10 weeks
Study: 17199783
Drug: Valproate +
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate + Carbamazepine (combined therapy)
Study: 17199783
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment (>10 years) with Valproate, Carbamazepine, and combined therapy
Study: 12644958
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg/h, continuous IV infusion for 5 hours)
Study: 12644958
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline solution, equal volume for 5 hours)
Study: 3510043
Drug: Barium suspension
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barium suspension with optimal viscosity (suspended with 65-70 ml water)
Study: 3510043
Drug: Barium suspension
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barium suspension with high viscosity (same batch number, suspended with different water amounts)
Study: 27163500
Drug: Belimumab 200
Normalized name: belimumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab 200 mg subcutaneously via autoinjector
Study: 27163500
Drug: Belimumab 200
Normalized name: belimumab 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab 200 mg subcutaneously via prefilled syringe
Study: 23028241
Drug: 0.5% lidocaine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% lidocaine, 10 mL (Group I)
Study: 23028241
Drug: 9 mL
Normalized name: ethanol 6.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mL of 0.5% lidocaine mixed with 1 mL of 6 mg of nonparticulate betamethasone (Group II)
Study: 16128861
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg acarbose
Study: 16128861
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g saccharose
Study: 1101231
Drug: Systematic psychologic
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic psychologic preparation and continued supportive care
Study: 1101231
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no systematic psychologic preparation and supportive care)
Study: 22043310
Drug: Patient administered
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient administered measures (Shared Decision Making Questionnaire, Control Preference Scale & Decisional Conflict Scale)
Study: 22043310
Drug: Patient administered
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient administered measures
Study: 12716672
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 14 mg . kg(‐)(1) . d(‐)(1)
Study: 12716672
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake of 15 mg . kg(‐)(1) . d(‐)(1)
Study: 10737537
Drug: Autologous tumor
Normalized name: DNP-Modified autologous tumor vaccine
DrugBank: DNP-Modified autologous tumor vaccine (DB17436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous tumor cell vaccine (AV) plus bCG with sequential administration of IFN gamma and IFN alpha
Study: 31379195
Drug: Olanzapine disintegrating
Normalized name: olanzapine Disintegrating Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine disintegrating tablets at a dose of 5 mg
Study: 20670088
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of different allergens for 24 months
Study: 20670088
Drug: Subcutaneous injections
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injections of different allergens for 18 months
Study: 12956739
Drug: MPL-adjuvanted grass
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPL-adjuvanted grass pollen allergy vaccine
Study: 9354313
Drug: TAK-044 25
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-044 25 mg
Study: 9354313
Drug: TAK-044 50
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-044 50 mg
Study: 9354313
Drug: TAK-044 100
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-044 100 mg
Study: 1342112
Drug: Chloroquine 50
Normalized name: chloroquine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 50 mg/Kg
Study: 1342112
Drug: Chloroquine 25
Normalized name: chloroquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 25 mg/Kg
Study: 3007066
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A administration
Study: 29577826
Drug: Effective pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective pain treatment
Study: 19242897
Drug: Experimental Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Group (EG) - group therapy consisting of psychoeducation, cognitive restructuring, stress management, relaxation and mindfulness techniques.
Study: 19242897
Drug: Experimental Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Group (EG) - group therapy.
Study: 18055982
Drug: Daily deferiprone
Normalized name: Twice-Daily deferiprone 1000 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily deferiprone (DFP) 75 mg/kg plus desferrioxamine (DFO) 40-50 mg/kg twice weekly
Study: 18055982
Drug: Daily deferiprone
Normalized name: Twice-Daily deferiprone 1000 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily deferiprone (DFP) monotherapy
Study: 18055982
Drug: Desferrioxamine (DFO)
Normalized name: DFO
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desferrioxamine (DFO) 40-50 mg/kg 5 days weekly (reference group)
Study: 16581423
Drug: Ranibizumab (Lucentis)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (Lucentis) at doses ranging from 0.3 to 2.0 mg, administered via 5, 7, or 9 intravitreal injections at 2- or 4-week intervals for 16 weeks.
Study: 2863148
Drug: Metoprolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (15 mg intravenous followed by 200 mg daily oral for 15 days)
Study: 29956886
Drug: Control VOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control VOO (80 mg kg‐1)
Study: 29956886
Drug: FVOO (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: FVOO (500 mg kg‐1)
Study: 29956886
Drug: FVOOT (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: FVOOT (500 mg kg‐1; 1:1)
Study: 20222114
Drug: CE-guided corticosteroid
Normalized name: Amidex ce surfactant
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE-guided corticosteroid injection
Study: 20222114
Drug: Accurate injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accurate injections
Study: 19100058
Drug: Nadroparin 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin 0.075 ml/10 kg (group I, n = 120)
Study: 19100058
Drug: Nadroparin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin 0.1 ml/10 kg (group II, n = 116)
Study: 15812629
Drug: ITBV guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITBV guided fluid therapy
Study: 15812629
Drug: CVP guided
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CVP guided fluid therapy
Study: 12529074
Drug: Recent drinking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent drinking history (RDH) measured using daily diary and timeline followback methods
Study: 8953876
Drug: Epidural buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine (0.2 mg) after combined spinal-epidural anesthesia (CSE group)
Study: 8953876
Drug: Epidural buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural buprenorphine (0.2 mg) after general anesthesia combined with epidural anesthesia (EPI + GEN group)
Study: 6977837
Drug: Acetylsalicylic acid,
Normalized name: Acetylsalicylic Acid, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylic acid, 1 gm daily, and anticoagulants
Study: 6977837
Drug: No antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic drugs
Study: 25595470
Drug: Diuretic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic treatment in acute decompensated heart failure (specific diuretic details not provided).
Study: 23279139
Drug: Aggressive heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive heart failure therapy
Study: 21976561
Drug: Artemisinin combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin combination treatment
Study: 12899797
Drug: Pre-operative chemotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative chemotherapy (1-2 cycles of cisplatinum-based regimen)
Study: 12899797
Drug: Post-operative chemotherapy
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative chemotherapy (2-4 cycles of cisplatinum-based regimen)
Study: 12899797
Drug: Pre-operative chemotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative chemotherapy (1-2 cycles) in stage II NSCLC
Study: 12899797
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to pre-operative chemotherapy
Study: 12899797
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pre-operative chemotherapy)
Study: 11885179
Drug: 3+ mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3+ mm diameter implants
Study: 11885179
Drug: 4+ mm
Normalized name: NEEDLE,PEN 31G,4MM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4+ mm diameter implants
Study: 11885179
Drug: 7 mm
Normalized name: potassium 7.7 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mm length implants
Study: 11885179
Drug: 16 mm
Normalized name: human regenerative tissue mtrx 16 mm TOPICAL SHEET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mm length implants
Study: 8614498
Drug: 0.1 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mmol/kg gadolinium-DTPA (standard dose)
Study: 8614498
Drug: 0.3 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mmol/kg gadolinium-DTPA (triple dose)
Study: 1410165
Drug: Self-administered smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered smoking re-exposure (smoking five cigarettes)
Study: 2856773
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg once daily
Study: 27824237
Drug: Focal extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal extracorporeal shock wave therapy (f‐ESWT) plus supervised eccentric training (SET) of the shoulder abductor muscles
Study: 27824237
Drug: Focal extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal extracorporeal shock wave therapy (f‐ESWT) only
Study: 27619826
Drug: Housing First
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing First + Assertive Community Treatment (HF+ACT)
Study: 19010976
Drug: Verbal threat
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal threat condition; specific details on dosage and duration not available.
Study: 19010976
Drug: Baseline condition;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline condition; specific details on dosage and duration not available.
Study: 11505247
Drug: Complementary therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary therapies (CTs) course for nursing assistants
Study: 3048103
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs together
Study: 31901945
Drug: Outpatient acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient acceptance and commitment therapy (O‐ACT)
Study: 28533306
Drug: Bendamustine-rituximab combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine-rituximab combination therapy
Study: 25908462
Drug: COSSACS -
Approvals — FDA: no, EMA: no, PMDA: no
Description: COSSACS - Continuation of prestroke antihypertensive therapy
Study: 22590838
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Metformin (500 mg tablets, two per twelve hours)
Study: 22590838
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + Metformin
Study: 16905220
Drug: Glycyrrhizin (6x
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin (6x weekly)
Study: 16905220
Drug: Glycyrrhizin (3x
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin (3x weekly)
Study: 16905220
Drug: Glycyrrhizin (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin (once weekly)
Study: 16905220
Drug: Glycyrrhizin treatment
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhizin treatment